EDEMA-PRODUCING ACTIVITY OF GROUP A STREPTOCOCCAL POLYSACCHARIDE AND ITS POSSIBLE ROLE IN THE PATHOGENESIS OF CELL WALL-INDUCED POLYARTHRITIS

By CHAMROEN CHETTY, ROGER R. BROWN, AND JOHN H. SCHWAB

From the Department of Bacteriology and Immunology, School of Medicine, University of North Carolina, Chapel Hill, North Carolina 27514

The group-specific polysaccharide (PS) isolated from group A streptococcal cell wall consists of a polyrhamnose backbone (alternating α-1,2 and α-1,3 linkages) which has β-1,3-linked N-acetyl-D-glucosamine (NADG) residues attached to the available 3 position in the backbone (1-4). Fung et al. showed that the PS molecule is heterogeneous because of varying amounts of NADG attached to the rhamnose backbone (5). The antibody raised against PS is reported to cross-react with a glycoprotein of connective tissue (6) and with antigens of thymus and skin epithelial cells (7). In various animal models of chronic inflammation induced by group A streptococcal cell walls (8-13), the PS played an important role in protecting the toxic peptidoglycan (PG) moiety from tissue lysozyme and other degradative enzymes (10, 14). Although the PS has been well characterized chemically and immunologically, there have not been any well-documented reports of a biological activity of this polymer.

In an earlier study (15), we observed that a spectrum of various sizes of PG-PS fragments was obtained by treatment of group A streptococcal cell walls with mutanolysin or phage-associated lysin. Some of these fragments induced edema in rats, and the severity of edema was related to the molecular weight of the PS polymer. The present study presents evidence that the active moiety responsible for the edematous responses is the PS and that this property is dependent upon the NADG epitope. Data are also presented that suggest that the edema-producing PS might play an important role in the pathogenesis of experimental cell wall-induced polyarthritis in rats (9, 16, 17).

Materials and Methods

Preparation of Cell Wall and Cell Wall Fragments. Purified cell walls were prepared by disruption of group A, type 3, strain D-58 streptococci in a Braun shaker (B. Braun Instruments, San Francisco, CA). Cell wall fragments were generated from the cell walls by sonic treatment (17) or by treatment with mutanolysin (15). The fragments obtained by treatment with mutanolysin included: high molecular weight (HMW) PG-PS (~500,000 mol wt), low molecular weight (LMW) PG-PS (~30,000 mol wt), and PG fragments; the PG-PS fragments obtained...
by sonic treatment were separated by differential centrifugation and included the 100S60 (~5.3 \times 10^6 mol wt) and 100P60 (~5.0 \times 10^7 mol wt). In certain experiments, the 100P60 was further fractionated by filtration through a column of Bio-Gel A-50m, and the fragments eluted in the void volume fractions were collected by centrifugation (100,000 g, 60 min, 4°C) and referred to as a filtered 100P60 preparation.

Preparation of Group-specific Polysaccharide. Group-specific PS was isolated from the cell walls of group A (type 3, strain D-58) and group A-variant (strain A486) streptococci according to the method described by Krause (18) with some modifications. A cell wall preparation was suspended in formamide (5 mg/ml) and extraction was performed at 150°C for 20 min. After being cooled overnight at 4°C, the extracted preparation was centrifuged (36,000 g, 30 min, 4°C), the supernatant was mixed with 2 vol of acid-alcohol (95% ethanol and 5% 1 N HCL), and the mixture was centrifuged (12,000 g, 30 min, 4°C). The PS in the alcoholic supernatant was precipitated by adding 5 vol of acid-acetone (99% acetone and 1% HCL) and a few crystals of sodium acetate to the supernatant. This was held at 4°C for 72 h. The acid-acetone precipitable carbohydrate was dissolved in distilled water, clarified by centrifugation, and treated with the acid-alcohol and acid-acetone once more. The PS obtained from the second acid-acetone treatment was suspended in distilled water, dialyzed against distilled water for 48 h at 4°C, and passed through Dowex-50 × 8 (200–400 mesh) cation exchange resin (Bio-Rad Laboratories, Richmond, CA) before lyophilization. The lyophilized PS was suspended in an appropriate amount of distilled water and was treated again with acid-alcohol and acid-acetone before use.

An aliquot of the group A PS was also treated with an N-acetyl-glucosaminidase to remove NADG from the rhamnose backbone. The enzyme was prepared from a soil bacillus (strain 2 aSm) as described by McCarty (4). The enzymatic digestion was performed by incubating a solution of the PS (60 mg in 22 ml of a buffer containing 0.5 M sodium citrate and 0.15 M NaCl, pH 6.0) with 8 ml of the partially purified enzyme (in 0.15 M NaCl). The mix were incubated at 25°C for 72 h and then heated at 100°C for 5 min to stop the reaction. The enzymatic-treated PS was clarified by centrifugation (25,000 g, 20 min, 4°C) and filtered through a column of Sephadex G-100. The fractions which contained rhamnose were pooled, dialyzed against deionized distilled water, and lyophilized.

Animals. We used outbred female Sprague-Dawley rats (Zivic-Miller Laboratory, Allison Park, PA) that weighed 120–160 g at the beginning of the experiments.

Iodination of Human Serum Albumin. Human serum albumin (HSA) (Cutter Laboratories, Inc., Berkeley, CA) was iodinated with 125I (Amersham Corp., Arlington Heights, IL) by solid-state lactoperoxidase as described by David and Reisfeld (19). The 125I-HSA had a specific activity of 94 \muCi/mg HSA, and was diluted with phosphate-buffered saline (PBS) before use.

Methods of Inducing and Scoring Edematous Response and Arthritis. Three routes of injection were used to induce edema in the rats, intravenous (i.v.), intraperitoneal (i.p.), and intra-articular (i.a.). When edema was induced by i.v. or i.p. injections, the samples were dissolved in and diluted with sterile PBS (0.04 M phosphate, 0.15 M NaCl, pH 7.2) and 0.4 ml samples were injected. Intra-articular injections were performed by injecting 10 \muI of control (PBS) or test samples in PBS through the Achilles tendon and above the calcaneous into the region of the tibio-talar joint. In all experiments, each rat was injected with the PBS control in the left joint and the test samples in the right joint. The intensity of edema in each limb was estimated on a scale 0–4 by gross observations, or by measuring the amount of 125I-HSA accumulated in the limbs. An earlier report (15) showed that there was an excellent correlation between the clinical scoring of edema and the amounts of 125I-HSA accumulation in the limb (r = 0.97, P < 0.001).

The time course of edema after the i.a. injection was determined by measuring 125I-HSA accumulation in the limbs at various times after the limbs were injected with the HMW PG-PS. The 125I-HSA was injected (i.v., 1.45 \times 10^{-3} \muCi/g body weight [g bw]) 1 h before the rats were scored for edema. The experiment was performed by injecting each of 24 rats (6 groups of 4 rats each) with 10 \muI of PBS into the left joint and 10 \muG of HMW PG-PS in 10 \muI PBS into the right joint. At 15, 30, and 60 min, and 4, 24, and 48 h after i.a. injection, one group of rats was scored for edema and immediately anesthetized by ether. The heart blood was withdrawn, and the left and the right limbs were removed. The amounts of 125I-HSA in the left and right
limbs and in the blood were determined with a Gamma counter (1197 series; Automatic Gamma Counting System, Searle Analytic Inc., Des Plaines, IL).

The 125I-HSA was also used to quantitate vascular permeability changes in various tissues after the rats were injected systemically with the PS. In these experiments, each member of a group of five rats was injected i.v. with 125I-HSA (1.18 × 10^{-3} μCi/gbw); after 30 min, the rats were injected i.v. with either PBS or with a PS preparation (6 μg/gbw). 30 min after the injection of PBS or PS, the rats were anesthetized by ether, the heart blood was collected, and various tissues were removed, including heart, lung, spleen, liver, thymus, kidney, skin (flank), muscle (trapezius), submandibular lymph node, mesenteric lymph nodes, ascending colon, as well as all four limbs. The amount of 125I-HSA in the tissue and in the blood were determined with the Gamma counter.

Arthritis was induced by a single i.p. injection of 100P60 preparations (in sterile PBS) at 12.75 or 10 μg rhamnose per gbw. The rats were scored for arthritis as described (9).

**Isolation of Edema-producing Activity from Cell Wall Sonicate.** After sonication of cell walls for 70 min (Branson Sonifier, model 350; Branson Sonic Power Co., Danbury, CT), the heterogeneous collection of fragments was centrifuged at 100,000 g for 60 min and the resulting supernatant fraction was labeled 100S60. The 100S60 fraction (300 mg) was dissolved in 10 ml of 0.01 M Tris/HCl (pH 7.4) and filtered through a column of Sepharose 6B equilibrated in the buffer. Cell wall fragments retained by the column were concentrated and washed with glass-distilled water in a stirred cell equipped with an Amicon UM05 membrane (Amicon Corp., Scientific Systems Div., Lexington, MA) and lyophilized. The materials in the lyophilized preparation (40 mg) were separated by DEAE-Sephacel ion-exchange chromatography into three fractions, designated F1, FII, and FIII. The F1 referred to the materials that did not bind to the column. The FII and FIII were isolated from the rhamnose-containing fractions that bound to the column and which were eluted with a linear gradient of NaCl (0-0.15 M). They were separated by Sephadex G-100 gel filtration based on differences in their sizes. The FII was eluted in the void volume, whereas the FIII was retained by the gel. All fractions which contained rhamnose were tested for edema-producing activity by i.a. injections.

**Molecular Weight Determinations.** Molecular weight of the PS was estimated by gel filtration using Dextran T fractions of known molecular weight as markers as previously described (15).

**Chemical Analyses.** Muramic acid and glucose were assayed as their alditol acetates by gas-liquid chromatography (20). Samples were hydrolyzed under vacuum for 3 h at 100°C with 2 N sulfuric acid before derivatization. Rhamnose was assayed according to Dische and Shettles (21). Glucosamine was determined by a modified Elson-Morgan method as described by Blumenkranz and Asboe-Hansen (22). Amino acid analyses were performed after the samples were hydrolyzed in 6 N HCl at 110°C in vacuo for 24 h. Hydrolyzed samples were lyophilized to dryness, redissolved in 0.2 M sodium citrate buffer (pH 2.2), and centrifuged to remove carboxylated material. The supernatant was applied to a gradient high pressure liquid chromatography system adapted to perform post-column derivatization amino acid analysis (23).

**Muramyl Dipeptide.** Muramyl dipeptide (MDP; N-acetyl-muramyl-L-alanyl-n-isoglutamine) and the analog (N-acetylmuramyl-D-alanyl-D-isoglutamine) were obtained from Sigma Chemical Co., St. Louis, MO. They were dissolved in sterile PBS, and the pH was adjusted to 7.4 with 1 N NaOH before use.

**Results**

**Edema Induced by PS and PG-PS Fragments.** The time course of edema developing in the limbs of rats injected with PS or PG-PS depended on the route of injection. When injected i.v., the kinetics of the edematous response was similar for PS and HMW PG-PS. Edematous swelling appeared in 5–10 min in both front and both hind limbs, reached maximal intensity by 30 min, began to disappear by 1 h, and was undetectable by 10 h. The minimum amount of PS required to give obvious edema was 1.0 μg/gbw (Table I). The PS isolated from group A-variant (strain A486) did not induce edema even when injected at 10 μg/gbw, and the glucosaminidase-treated group A
Table 1
Response of Rats to i.v. Injection of PS

| PS                  | Dose (µg/gbw) | Number positive/number injected | Average score of positive rats at 30 min postinjection* |
|---------------------|---------------|---------------------------------|--------------------------------------------------------|
| Group A, strain D58 | 1.00          | 1/5                             | 1.0                                                    |
|                     | 2.50          | 5/5                             | 1.80 ± 1.30                                            |
|                     | 5.00          | 5/5                             | 10.60 ± 3.29                                           |
|                     | 10.00         | 4/4                             | 14.75 ± 1.66                                           |
| Group A-variant strain A486 | 4.86          | 0/5                             |                                                        |
|                     | 10.00         | 0/4                             |                                                        |
| Enzyme-treated group A, strain D58 | 5.00          | 0/5                             |                                                        |
|                     | 10.00         | 1/4                             | 2.0                                                    |
| PBS control         | 0.4 ml        | 0/5                             |                                                        |

* A positive response was indicated by the appearance of edema in the front and hind limbs. A scale of 0-4 was used to estimate the intensity of edema of each limb; therefore, the maximum total score per rat was 16 (mean ± 1 SD).

PS was much less active in inducing edema than was the untreated preparation (Table I).

Edematous responses could also be induced locally in the limbs when the edema-producing PG-PS or PS preparations were injected i.a. (Table II). Edema was not accompanied by detectable erythema and microscopic examination of tissue sections gave no evidence of erythrocyte or leukocyte infiltration into edematous joints. The time course of edematous responses in the limbs of rats (determined by measurements of 125I-HSA accumulation at various times) was similar to those seen after i.v. injection, with the exception that the increase in vascular permeability persisted at a low level for at least 24 h (Fig. 1). The dose-response curve of edema after i.a. injection of HMW PG-PS is shown in Fig. 2.

Intraperitoneal injection of the group A PS at 15 µg/gbw resulted in the appearance of edema at 60 min. The edematous response reached maximal intensity at 2 h, began to decline, and usually was not observable at 15 h.

Analysis of PS Preparations by Gel Filtration. The PS from group A streptococcal cell wall was retained by Sephadex G-100 and had a size slightly larger than that of the PS isolated from the group A-variant (Fig. 3 A-B). Treatment of group A PS with glucosaminidase for 72 h resulted in a partial removal of glucosamine from the rhamnose backbone. Enzymatic digestion of the PS was indicated by the appearance of a second peak of glucosamine which eluted close to the bed volume (Vt) of the Sephadex G-100 column (Fig. 4). In addition, the enzyme-treated PS had an average size slightly smaller than that of the untreated group A PS.

Isolation of Edema-producing Activity from Cell Wall Sonicate. Edema-producing cell wall fragments in the 100S60 fraction of the cell wall sonicate were retained by Sepharose 6B and were very heterogenous in size. Some of these fragments (FIII) did not bind to the column of DEAE-Sephacel, which was equilibrated with 0.01 M Tris/HCl (pH 7.35), whereas other fragments (FII and FIII) bound to the column and were eluted by a linear 0-0.13 M NaCl gradient. The FII was excluded by the Sephadex G-100 column but the FIII was retained by the column and had a $K_w$ of 0.29, $M_N = 26,000$. All fractions induced edematous responses (Table II).
### Table II

Response of Rats to i.a. Injection of Various PG-PS, PS, and PG Fragments

| Preparation | Dose | Number positive/number injected | Average score of positive rats at 30 min postinjection* |
|-------------|------|--------------------------------|------------------------------------------------------|
| **Fragments generated by mutanolysin** |      |                                |                                                      |
| HMW PG-PS   | 2.50 | 5/5                            | 0.88 ± 0.25                                          |
| (~500,000 mol wt) | 10.00 | 5/5                            | 2.25 ± 0.29                                          |
| LMW PG-PS   | 10.00 | 5/5                            | 1.44 ± 0.52                                          |
| (~30,000 mol wt) |      |                                |                                                      |
| LMW PG‡     | 20.00 | 0/5                            |                                                       |
| Group A PS  | 0.25  | 2/5                            | 0.50                                                 |
|             | 1.25  | 5/5                            | 1.05 ± 0.67                                          |
|             | 3.00  | 5/5                            | 2.29 ± 0.27                                          |
| Group A-variant PS |    |                                |                                                      |
| F1          | 2.50  | 4/4                            | 0.63 ± 0.14                                          |
|             | 10.00 | 4/4                            | 2.75 ± 0.29                                          |
| FII         | 2.50  | 5/5                            | 0.60 ± 0.55                                          |
|             | 10.00 | 5/5                            | 1.75 ± 0.29                                          |
| FIII        | 2.50  | 5/5                            | 0.70 ± 0.45                                          |
|             | 10.00 | 5/5                            | 2.50 ± 0.41                                          |
| LMW fragments derived from 100S60 (retained by Bio-Gel A-50m) | 10.00 | 5/5 | 1.20 ± 0.57 |
| MDP         | 300.00 | 0/5                            |                                                       |
| MDP analog  | 300.00 | 0/5                            |                                                       |
| Lipopolysaccharide (Salmonella, typhimurium) | 0.10 | 0/5 |                                                       |
|             | 1.00  | 0/5                            |                                                       |
|             | 10.00 | 0/5                            |                                                       |
| PBS         | 10 µl | 0/5                            |                                                       |

* A positive response was the appearance of edema in the right limb (sample-injected limb). A scale of 0-4 was used to estimate the intensity of edema of the limb (Mean ± 1 SD).

‡ Retained by Sephadex G-25 (15).

![Fig. 1](image-url)  

**Fig. 1.** Time-course of edema after i.a. injection of HMW PG-PS. (●) 125I-HSA in the HMW PG-PS injected limb; (○) PBS-injected limb. Each dot represents the mean of four rats and the bracket represents the standard error of the mean. There were no significant differences in the level of 125I-HSA in the blood (cpm/ml) of the 24 rats.

**Chemical Analyses (Table III).** The PS preparations used in our studies contained no detectable amounts of muramic acid (<0.3% wt/wt), contained <0.3% alanine, glutamic acid, and lysine and contained only small amounts of other amino acids.
EDEMA INDUCED BY GROUP A STREPTOCOCCAL POLYSACCHARIDE

Fig. 2. Dose response curve of edema induced by i.a. injection of the HMW PG-PS. Each group of four rats was injected with HMW PG-PS (0.1-50 μg/limb). Each dot represents the mean ± SEM.

Fig. 3. Sephadex G-100 elution profiles of polysaccharides isolated from (A) group A strain D58 and (B) group A-variant strain A486 streptococi. A sample (6 mg of group A polysaccharide or 10 mg of group A-variant polysaccharide) was dissolved in 1 ml of 0.01 M Tris/HCl (pH 7.4), applied to a column of Sephadex G-100 (2.6 × 94 cm), and eluted with Tris/HCl at 4°C at a flow rate of 18 ml/h. Fractions (4.6 ml) were assayed for rhamnose (●) and glucosamine (○).

(<0.05% wt/wt). The enzyme-treated PS had significantly lower glucosamine content than did the untreated PS. The composition of the various edema-producing fragments in the 100S60 indicated the heterogeneity of these fragments. The F1 consisted of the PS and possibly some membranous contaminants, whereas the FII and FIII consisted primarily of PG-PS fragments. The ratio of the PS to the PG components of the FIII was much higher than that of the FII.

Vascular Permeability Changes after i.v. Injection of Edema-producing PS. 30 min after i.v. injection of group A PS (6 μg/gbw), the amount of 125I-HSA in the blood decreased by 34% when compared with the control group (Table IV). The permeability increase of all four limbs was highly significant (P < 0.001), and the increase in the muscle and submandibular lymph node was of questionable significance (P < 0.05). However,
when the experiment was repeated, the increase in vascular permeability in the muscle and submandibular lymph node was not observed. On the other hand, there was a slight decrease in the vascular permeability in the mesenteric lymph nodes ($P < 0.01$) and ascending colon ($P < 0.05$).

**Edema-producing Activity and Arthritogenic Activity of 100P60.** Preliminary experiments indicated that the 100P60 fraction of the cell wall sonicate (unfiltered 100P60) contained small amounts of edema-producing PG-PS fragments (Table II). These fragments were retained by a Bio-Gel A-50 m column and, thus, could be separated from the 100P60 (excluded by the gel). The 100P60, which was free of edema-producing activity (filtered 100P60), was significantly less arthropathic than the unfiltered 100P60 when compared on the basis of equal amounts of rhamnose injected (Fig. 5). The differences in the severity of arthritis induced by these preparations were most easily observed during the first 14 d ($P < 0.01$) and between day 52 and day 60 ($P < 0.05$). The arthropathic activity of the filtered 100P60 was significantly increased when it was mixed with the edema-producing PS before injection (Fig. 6).
**Table IV**  
Vascular Permeability Changes after i.v. Injection of Group A PS and PBS Control

| Tissue                  | PBS (cpm/30 min) | PS (cpm/30 min) | P Value |
|-------------------------|------------------|-----------------|---------|
| Blood                   | 15,728 ± 1,815‡  | 10,427 ± 2,741  | < 0.01  |
| Limbs                   |                  |                 |         |
| Right front             | 1,134 ± 176      | 6,470 ± 1,620   | < 0.001 |
| Left front              | 1,172 ± 296      | 6,056 ± 833     | < 0.001 |
| Right hind              | 1,062 ± 200      | 3,120 ± 504     | < 0.001 |
| Left hind               | 990 ± 190        | 3,580 ± 155     | < 0.001 |
| Heart                   | 4,710 ± 1,318    | 3,641 ± 792     | NS§     |
| Lung                    | 3,976 ± 517      | 3,646 ± 941     | NS      |
| Spleen                  | 1,978 ± 162      | 1,949 ± 412     | NS      |
| Liver                   | 3,374 ± 438      | 3,248 ± 580     | NS      |
| Thymus                  | 860 ± 378        | 788 ± 151       | NS      |
| Kidney                  | 5,004 ± 678      | 4,506 ± 357     | NS      |
| Skin (flank)            | 971 ± 112        | 1,022 ± 175     | NS      |
| Muscle (trapezius)      | 451 ± 82         | 571 ± 162       | P < 0.05|
| Submandibular lymph node| 2,064 ± 280      | 3,981 ± 1,637   | P < 0.05|
| Mesenteric lymph node   | 2,269 ± 161      | 1,724 ± 313     | P < 0.01|
| Ascending colon         | 951 ± 136        | 782 ± 133       | P < 0.05|

* Mean ± standard deviation (five rats), 30 min postinjection.
‡ cpm/ml.
§ Not significant.

**Fig. 5.** Arthropathic activity of an unfiltered and a filtered 100P60 fraction of PG-PS. Each 100P60 preparation was injected i.p. into a group of 10 rats at 12.75 μg rhamnose/gbw. The average score of arthritis from all 10 rats in the group is expressed as mean joint score ± standard error of the mean. The level of significance between the two groups was calculated for each time point by Student's t test. (●) unfiltered 100P60; (○) filtered 100P60.

**Discussion**

The group-specific PS isolated from group A streptococcal cell walls selectively induces a rapid but transient edematous response in the limbs of rats that is not detected in other tissues examined. The time-course of edema depends on the route of injection. To our knowledge, this is the first documented report of a biologic activity of the group A PS. The PS preparations used in these studies contained <1% (wt/wt) total amino acids and did not contain muramic acid detectable by GLC or amino acid analyzer. Therefore, contamination with PG (if any) and other peptides was minimal. Other evidence to support the idea that the activity is associated with the PS include the findings that isolated PG fragments did not induce edema and that
the edema-producing activity was markedly reduced by glucosaminidase. This effect of glucosaminidase, combined with absence of activity of group A variant PS, indicates that the NADG epitope is a critical structure for this property.

Morisaki et al. (24) reported that mutanolysin digests of group A streptococcal cell wall (which was rich in group A carbohydrate) could activate murine polyclonal B cells. Because the mutanolysin digests consist of PG-PS complexes (15, 24), and isolated PG has been described as a polyclonal B cell activator (25), it is difficult to ascribe the mitogenic activity to the PS. Recently, it was suggested that the PS derived from *Streptococcus pyogenes* OK-432 augmented natural killer activity of human peripheral blood lymphocytes in vitro (26). The chemical compositions of the PS used in their study was not reported; thus, the possibility of PG and other cell wall and/or membranous contaminants in the PS preparation cannot be excluded.

Our findings suggest that the edema-producing PG-PS and PS polymers might play a role in the pathogenesis of cell wall-induced polyarthritis, although they are not themselves arthropathogenic. The PS caused a selective increase in vascular permeability in the limbs, and this vascular change might be the initial event that allows localization of the arthropathic cell wall fragments in the synovial tissue. Our speculation is based on the finding that the edema-producing PS increased both the incidence and the severity of arthritis induced by the 100P60 (Figs. 5, 6). Experiments are in progress to examine the effect of the PS on the distribution and degradation of arthropathic cell wall fragments in rat tissues. These experiments involve the use of solid-phase radioimmunoassays that were recently developed in this laboratory (27).

The edematous response is transient and limited to a serous exudate with no evidence of erythrocyte or leukocyte movement. Whether this effect on vascular endothelium of the joints is a direct action of PS or involves activation of inflammatory mediators is unknown at this time. The remarkable selectivity for the limbs suggests that a specific receptor for the PS may be located in the synovial or the periarticular vascular endothelium. Blood vessels of similar size and structure in different tissues...
have been shown to vary also in their response to histamine-type permeability factors (28-31).

Summary

Edematous responses were induced in the limbs of Sprague-Dawley rats by intravenous, intraperitoneal, or intra-articular injections of group-specific polysaccharide (PS) isolated from the cell walls of group A streptococci. After intravenous injection of the edema-producing PS, vascular permeability increase (measured by $^{125}$I-human serum albumin) was detected in the limbs, but not in the heart, lungs, spleen, liver, thymus, kidney, skin, skeletal muscle, submandibular lymph nodes, mesenteric lymph nodes, or ascending colon. This indicates a selective effect on vascular endothelium of the joints. Evidence to suggest that the edema-producing activity of the PS might play an important role in the pathogenesis of cell wall-induced polyarthritis included the following: (a) the presence of edema-producing activity in arthropathogenic cell wall preparations; (b) cell wall preparations without edema-producing activity were significantly less active in inducing arthritis than were those which contained edema-producing activity; and (c) the addition of edema-producing PS to cell wall preparations increased both the incidence and the severity of arthritis.

The expert assistance of Louise Cockey and Olina McLean is gratefully acknowledged.

Received for publication 4 November 1982.

References

1. Coligan, J. E., T. J. Kindt, and R. M. Krause. 1978. Structure of the streptococcal groups A, A-variant and C carbohydrates. *Immunochemistry.* 15:755.
2. Estrada-Parra, S., M. Heidelberger, and P. A. Rebers. 1963. Immunochemical properties of the periodate-oxidized polysaccharide of group A hemolytic streptococcus. *J. Biol. Chem.* 238:510.
3. Krause, R. M., and M. McCarty. 1961. Studies on the chemical structure of streptococcal cell walls. I. Identification of a mucopeptide in the cell walls of group A and A-variant streptococci. *Exp. Med.* 114:127.
4. McCarty, M. 1956. Variation in the group-specific carbohydrate of group A streptococci. II. Studies on the chemical basis for serological specificity of the carbohydrates. *J. Exp. Med.* 104:629.
5. Fung, J. C., K. Wichcr, and M. McCarty. 1982. Immunochemical analysis of streptococcal group A, B, and C carbohydrates with emphasis on group A. *Infect. Immun.* 37:209.
6. Goldstein, I., P. Rebeyrotte, J. Parlebras, and B. Halpern. 1968. Isolation from heart valves of glycopeptides which share immunological properties with *Streptococcus haemolyticus* group A polysaccharides. *Nature (Lond.)* 219:866.
7. Lyampert, I. M., L. V. Beletskaya, N. A. Borodiyuk, E. V. Gnezditskaya, I. I. Rassokhina, and T. A. Danilova. 1976. A cross-reactive antigen of thymus and skin epithelial cells common with the polysaccharide of group A streptococci. *Immunology.* 31:47.
8. Cromartie, W. J., and J. G. Craddock. 1966. Rheumatic-like cardiac lesions in mice. *Science (Wash. DC.)* 154:285.
9. Cromartie, W. J., J. G. Craddock, J. H. Schwab, S. K. Anderle, and C. Yang. 1977. Arthritis in rats after systemic injection of streptococcal cell or cell walls. *J. Exp. Med.* 146:1585.
10. Ohanian, S. H., and J. H. Schwab. 1967. Persistence of group A streptococcal cell wall related to chronic inflammation of rabbit dermal connective tissue. J. Exp. Med. 125:1137.
11. Ohanian, S. H., J. H. Schwab, and W. J. Cromartie. 1969. Relation of rheumatic-like cardiac lesions of the mouse to localization of group A streptococcal cell wall. J. Exp. Med. 129:37.
12. Schwab, J. H., and W. J. Cromartie. 1957. Studies on a toxic cellular component of group A streptococci. J. Bacteriol. 74:673.
13. Schwab, J. H., W. J. Cromartie, S. H. Ohanian, and J. G. Craddock. 1967. Association of experimental chronic arthritis with the persistence of group A streptococcal cell walls in the articular tissue. J. Bacteriol. 94:1728.
14. Schwab, J. H., and S. H. Ohanian. 1967. Degradation of streptococcal cell wall antigens in vivo. J. Bacteriol. 94:1346.
15. Chetty, C., D. G. Klapper, and J. H. Schwab. 1982. Soluble peptidoglycan-polysaccharide fragments of bacterial cell wall which induced acute inflammation. Infect. Immun. 38:1010.
16. Clark, R. L., J. T. Cuttino, Jr., S. K. Anderle, W. J. Cromartie, and J. H. Schwab. 1979. Radiologic analysis of arthritis in rats after systemic injection of streptococcal cell walls. Arthritis Rheum. 22:25.
17. Fox, A., R. R. Brown, S. K. Anderle, C. Chetty, W. J. Cromartie, H. Gooder, and J. H. Schwab. 1982. Arthropathic properties related to the molecular weight of peptidoglycan-polysaccharide polymers of streptococcal cell walls. Infect. Immun. 35:1003.
18. Krause, R. M. 1967. Preparation of cell-wall antigens from gram-positive bacteria. Methods Immunol. Immunochim. 1:34.
19. David, G. S., and R. A. Reisfeld. 1974. Protein iodination with solid state lactoperoxidase. Biochemistry. 13:1014.
20. Sawardeker, J. S., J. H. Sloneker, and A. Jeanes. 1965. Quantitative determination of monosaccharides as their alditol acetates by gas liquid chromatography. Anal. Chem. 37:1602.
21. Dische, A., and L. B. Shettles. 1948. A specific color reaction of methyl pentose and a spectrophotometric micromethod for their determination. J. Biol. Chem. 175:595.
22. Blumenkrantz, N., and G. Asboe-Hansen. 1976. An assay for total hexosamine and a differential assay for glucosamine and galactosamine. Clin. Biochem. 9:269.
23. Klapper, D. G. 1982. A new low cost, fully automated amino acid analyzer using a gradient HPLC. In Methods in Protein Sequence Analyses. M. Elzinga, editor. Humana Press, Clifton, NJ. 509-515.
24. Morisaki, I., S. M. Michalek, S. Hamada, W. J. Koopman, N. Okahashi, S. Kotani, and J. R. McGhee. 1982. Cell wall carbohydrate from Streptococcus pyogenes activates murine B cells. Fed. Proc. 41(3):305.
25. Damais, C., Bona, L. Chedid, J. Fleck, C. Nauclier, and J. P. Martin. 1975. Mitogenic effect of bacterial peptidoglycans possessing adjuvant activity. J. Immunol. 115:268.
26. Wakasugi, H., K. Oshimi, T. Kasahara, M. Miyata, and Y. Morioka. 1982. In vitro augmentation of human natural killer (NK) cell activity by a streptococcal preparation OK-432 and its extracts, protein M, and polysaccharides. Int. Arch. Allergy Appl. Immunol. 67:222.
27. Eisenberg, R., A. Fox, J. J. Greenblatt, S. K. Anderle, W. J. Cromartie, and J. H. Schwab. 1982. Measurement of bacterial cell wall in tissues by solid phase radioimmune assay. Correlation of distribution and persistence with experimental arthritis in rats. Infect. Immun. 38:127.
28. Cunningham, A. L., and J. V. Hurley. 1972. Alpha-naphthyl-thiouria-induced pulmonary oedema in the rat: a topographic and electron-microscopic study. J. Pathol. 106:225.
29. Hurley, J. V., B. Edwards, and K. N. Ham. 1970. The response of newly formed blood vessels in healing wounds to histamine and other permeability factors. Pathology. 2:133.
30. Hurley, J. V., and A. McQueen. 1971. The response of the fenestrated vessels of the small intestine of rats to application of mustard oil. *J. Pathol.* 105:21.

31. Pietra, G. G., J. P. Szidon, M. M. Leventhal, and A. P. Fishman. 1971. Histamine and interstitial pulmonary edema in the dog. *Circulation Res.* 29:323.